Start Submission Become a Reviewer

Reading: Neurologic disorders and COVID-19


A- A+
Alt. Display


Neurologic disorders and COVID-19


Saman B. Gunatilake

Editor, Emeritus Professor of Medicine and Consultant Neurologist, LK
X close


SARS-CoV-2 with its wide range of disease severity ranging from asymptomatic carriers to severe respiratory compromise and death, is still with us. High rates of infection and subsequent long-term sequelae have raised significant concerns, particularly for those with underlying medical illnesses, who may be more severely affected. This includes not only those treated with immunosuppressive therapies for their neurologic disorders (e.g., myasthenia gravis or multiple sclerosis [MS]) but also those with significant functional disability from their disease and elderly patients with a history of cerebrovascular disease, Parkinson disease and dementia. As neurologic disorders are common, the effect of SARS-CoV-2 on patients with neurologic illnesses poses a substantial public health risk. Prioritizing this population is critical when considering the risks and benefits of vaccination.

Keywords: Neurology, COVID-19
How to Cite: Gunatilake SB. Neurologic disorders and COVID-19. Sri Lanka Journal of Neurology. 2021;8(1):1–2. DOI:
Published on 01 Dec 2021.


  • PDF (EN)

    comments powered by Disqus